Illumina, Inc. (ILMN)
Market Cap | 16.81B |
Revenue (ttm) | 4.49B |
Net Income (ttm) | -1.29B |
Shares Out | 159.30M |
EPS (ttm) | -8.15 |
PE Ratio | n/a |
Forward PE | 41.42 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,397,720 |
Open | 106.19 |
Previous Close | 105.50 |
Day's Range | 105.48 - 107.56 |
52-Week Range | 86.58 - 190.31 |
Beta | 1.20 |
Analysts | Buy |
Price Target | 158.28 (+50.01%) |
Earnings Date | Aug 7, 2024 |
About ILMN
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regio... [Read more]
Financial Performance
In 2023, Illumina's revenue was $4.50 billion, a decrease of -1.75% compared to the previous year's $4.58 billion. Losses were -$1.16 billion, -73.64% less than in 2022.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is $158.28, which is an increase of 50.01% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/k/n/medical24-2502396.jpg)
Illumina Takes a $1.47 Billion Charge Related to Its Spinoff of GRAIL
The breakup with GRAIL (GRAL) was costly for Illumina (ILMN).
![](https://cdn.snapi.dev/images/v1/v/1/medical15-2500964.jpg)
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
![](https://cdn.snapi.dev/images/v1/u/e/illumina-completes-spin-off-of-2498296.jpg)
Illumina Completes Spin-Off Of GRAIL
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitaliz...
![](https://cdn.snapi.dev/images/v1/t/c/medical9-2493983.jpg)
Grail bets big on flagship cancer test after spin-off from Illumina
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers a...
![](https://cdn.snapi.dev/images/v1/o/s/press2-2493806.jpg)
Illumina completes the divestiture of GRAIL
GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25 Illumina to issue second quarter 2024 results on August 6; leadership to present Strategy Update on August 13 SAN DIEGO...
![](https://cdn.snapi.dev/images/v1/g/y/illumina-to-spin-off-grail-uni-2473783.jpg)
Illumina To Spin-Off GRAIL Unit On June 24
On June 3, 2024, Illumina's (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on ...
![](https://cdn.snapi.dev/images/v1/a/u/press7-2473323.jpg)
Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
Latest version includes a prebuilt pangenome capturing more genetic diversity, reducing ancestry bias, and improving accuracy SAN DIEGO , June 11, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a ...
![](https://cdn.snapi.dev/images/v1/i/4/press11-2470805.jpg)
Illumina Inc. (ILMN): 2024 Company Profile, Product Pipeline Analysis, and Ongoing Clinical Trials Insights
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a sourc...
![](https://cdn.snapi.dev/images/v1/q/2/up-nearly-15-in-a-week-will-il-2470789.jpg)
Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels?
Illumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company's decis...
![](https://cdn.snapi.dev/images/v1/a/6/press4-2461395.jpg)
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost
SAN DIEGO , June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemist...
![](https://cdn.snapi.dev/images/v1/j/p/wz5np67gvbjxfj4wzxxr7opfhu-2460309.jpg)
Illumina to spin off Grail in June
Illumina , a maker of gene sequencing machines, said on Monday it expected to spin off cancer test maker Grail.
![](https://cdn.snapi.dev/images/v1/a/h/press12-2460225.jpg)
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
"When-issued" trading expected to begin on or about June 12, 2024 Record date for distribution of GRAIL shares will be June 13, 2024 Distribution date for GRAIL shares anticipated to be June 24, 2024 ...
![](https://cdn.snapi.dev/images/v1/n/k/press5-2451663.jpg)
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome ap...
![](https://cdn.snapi.dev/images/v1/t/h/press20-2450519.jpg)
Illumina releases 2023 Corporate Social Responsibility Report
SAN DIEGO , May 28, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility ...
![](https://cdn.snapi.dev/images/v1/a/c/press6-2449774.jpg)
Integrated Biosciences Joins Illumina Ventures Labs to Design Novel Therapeutics Targeting the Transcriptome
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #age--Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age...
![](https://cdn.snapi.dev/images/v1/l/s/press3-2440370.jpg)
Anna Richo joins Illumina's Board of Directors
Ms. Richo brings more than 30 years of global legal, compliance, and regulatory experience to Illumina's Board SAN DIEGO , May 20, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today t...
![](https://cdn.snapi.dev/images/v1/a/l/conf3-2433291.jpg)
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bernstein's 40th Annual Strategic Deci...
![](https://cdn.snapi.dev/images/v1/0/d/press7-2426550.jpg)
GRAIL to Host Capital Markets Day
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC announced today that it will host a virtual Capital Markets Day.
![](https://cdn.snapi.dev/images/v1/0/5/press3-2413468.jpg)
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
GRAIL to host Capital Markets Day on May 13, 2024 SAN DIEGO , May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement wit...
![](https://cdn.snapi.dev/images/v1/l/n/qvyzuj32tbkgrbdmrkevevtz2u-2408037.jpg)
Illumina reaffirms annual revenue forecast over continued sluggish demand
Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.
![](https://cdn.snapi.dev/images/v1/v/r/press6-2407516.jpg)
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis) Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for ...
2 Cheap Growth Stocks to Buy During 2Q
These undervalued stocks from the growth side of the Morningstar style box are among our analysts' favorites today. 00:00 Introduction 00: 31 Adobe ADBE 01:09 Illumina ILMN I'm Susan Dziubinski with M...
![](https://cdn.snapi.dev/images/v1/j/p/press4-2369027.jpg)
Illumina's planned divestment of GRAIL approved by the European Commission
SAN DIEGO , April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment pla...
![](https://cdn.snapi.dev/images/v1/k/8/cnxa3u4ezricjp5ymsj5ptbl6u-2368714.jpg)
EU approves Illumina's plan to divest cancer test maker Grail
The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail , it said in a statement on Friday.
![](https://cdn.snapi.dev/images/v1/r/y/cnxa3u4ezricjp5ymsj5ptbl6u-2364197.jpg)
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.